Enzymatic activation of caged tetrazines for cell-specific bioconjugation
Preprint
- 29 January 2024
- preprint
- Published by American Chemical Society (ACS) in ChemRxiv
Abstract
Tetrazine ligation techniques have evolved into a versatile tool set for bioconjugation. Despite their numerous applications, highly reactive tetrazines can suffer from long-term instability and off-target reactivity, and achieving cell-specific bioconjugation remains challenging. Tetrazine caging techniques intend to overcome these issues by achieving spatial and temporal control over tetrazine activation from stable dihydrotetrazine derivatives. Here we explore enzyme-initiated tetrazine uncaging, allowing for controlled release of reactive tetrazines by enzymes overexpressed in specific cell types. Using a modular synthetic strategy, we connected four distinct enzyme-cleavable motifs to caged tetrazine derivatives using a self-immolative linker unit. We validated cell-specific release using penicillin G amidase (PGA), which we genetically encoded into HEK293Ts. Cells expressing PGA were able to activate tetrazines which subsequently reacted with a dienophile-protected doxorubicin, lowering viability. In contrast, treatment of mammalian cells lacking PGA showed no reduction in cell viability. Additionally, we generated enzyme-cleavable conjugates that are hydrolyzed by enzymes commonly exploited for drug delivery in human cells, including esterases, cathepsin B, and alkaline phosphatases. We demonstrate cell-type specific activation of tetrazines based on the varying expression levels of alkaline phosphatases in different cell lines. Specifically, we compared tetrazine activation in the osteosarcoma cell line SAOS-2, known for its exceptionally high ALP expression levels, to cells that express lower levels of ALP, the colorectal adenocarcinoma cell line HT-29 and the stromal cell line HS-5. Overall, we find that tetrazine release from enzyme-cleavable tetrazine derivatives is dependent on the enzyme activity present in specific cells and therefore constitutes a promising technique for cell-type specific bioconjugation.Keywords
All Related Versions
This publication has 46 references indexed in Scilit:
- A Patent Review on FDA‐Approved Antibody‐Drug Conjugates, Their Linkers and Drug PayloadsChemMedChem, 2022
- Loncastuximab Tesirine: First ApprovalDrugs, 2021
- Antibody–drug conjugates: Recent advances in linker chemistryActa Pharmaceutica Sinica B, 2021
- SQ3370 Activates Cytotoxic Drug via Click Chemistry at Tumor and Elicits Sustained Responses in Injected and Non‐Injected LesionsAdvanced Therapeutics, 2021
- Tetrazine Carbon Nanotubes for Pretargeted In Vivo “Click‐to‐Release” Bioorthogonal Tumour ImagingAngewandte Chemie International Edition, 2020
- Stable, Reactive, and Orthogonal Tetrazines: Dispersion Forces Promote the Cycloaddition with IsonitrilesAngewandte Chemie International Edition, 2019
- Click to Release: Instantaneous Doxorubicin Elimination upon Tetrazine LigationAngewandte Chemie International Edition, 2013
- Live‐Cell Imaging of Cyclopropene Tags with Fluorogenic Tetrazine CycloadditionsAngewandte Chemie International Edition, 2012
- Zur Kenntnis von Reaktionen des 1,2,4,5‐Tetrazin‐3,6‐dicarbonsäure‐dimethylesters mit NucleophilenEuropean Journal of Inorganic Chemistry, 1982
- Alkaline phosphatase in HT-29, a human colon cancer cell line: Influence of sodium butyrate and hyperosmolalityArchives of Biochemistry and Biophysics, 1981